UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

MYLAN PHARMACEUTICALS INC., Petitioner,

v.

ASTRAZENECA AB, Patent Owner.

Case IPR2015-01340 Patent RE44,186 E

DECLARATION OF CHRISTINE S. MEYER, PH.D. August 2, 2016

CONFIDENTIAL INFORMATION - SUBJECT TO PROTECTIVE ORDER




Table of Contents

I.	INTRODUCTION1
А	A. PROFESSIONAL QUALIFICATIONS AND EXPERTISE
В	8. RETENTION AND ASSIGNMENT
C	COMPENSATION
D	D. INFORMATION CONSIDERED
E	. SUMMARY OF OPINIONS
II. BACKGROUND	
А	A. ASTRAZENECA AND SAXAGLIPTIN
В	
C	2. The Patent at Issue
III.	THE PURPOSE OF AN ANALYSIS OF COMMERCIAL SUCCESS11
IV. THE COMMERCIAL SUCCESS OF ONGLYZA [®] AND	
	KOMBIGLYZETM XR 13
A	A. THE MARKETPLACE PERFORMANCE OF ONGLYZA [®] AND KOMBIGLYZE TM XR IS
	DRIVEN BY THE CLAIMED FEATURES OF THE RE'186 PATENT14
E	8. ONGLYZA [®] AND KOMBIGLYZE TM XR ARE A MARKETPLACE SUCCESS16
C	C. THE IMPORTANCE OF EXTRINSIC FACTORS IN THE SALES OF ONGLYZA [®] AND
	Kombiglyze TM XR

I, Christine S. Meyer, hereby declare as follows.

I. INTRODUCTION

A. Professional Qualifications and Expertise

1. I am an economist and Senior Vice President at National Economic Research Associates, Inc. ("NERA"). NERA is a firm of consulting economists that was founded in 1961 and provides research and analysis in economics, including analysis in the areas of competition, regulation, and finance. I joined the firm in 2000 and have worked since then mainly in the areas of the economics of intellectual property, antitrust analysis, and the evaluation of commercial damages. I have testified as an expert witness in the United States District Court, the Supreme Court of the State of New York, the Federal Court of Canada, and the High Court of Justice in England.

2. Since joining NERA, I have analyzed economic issues in a wide variety of cases. As part of my work, I have written expert reports and declarations related to commercial success in patent cases for both District Court and Patent Trial and Appeal Board proceedings. I have also analyzed damages arising from patent infringement; irreparable harm as related to potential injunctions in patent cases; and the value of several patents, licenses, and potential business acquisitions. I have written articles and book chapters about patent infringement damages and have been asked to speak about economic issues related to intellectual property on numerous occasions, including by the U.S. Federal Trade Commission in its hearings entitled "*The Evolving IP Marketplace*." I have been involved in many cases involving a variety of technologies across a broad range of industries, including pharmaceutical products, medical devices, and consumer products.

3. I received my bachelor's degree with a concentration in economics from the United States Military Academy at West Point and my Ph.D. in economics from the Massachusetts Institute of Technology. I taught economics and statistics at Bentley College and Colgate University. A list of my prior testimony and publications can be found in my *curriculum vitae*, which is appended to this declaration as Exhibit 2060.

B. Retention and Assignment

4. NERA has been retained by Finnegan, Henderson, Farabow, Garrett & Dunner, LLP, counsel for AstraZeneca AB ("AstraZeneca" or "Patent Owner") for the above-captioned *inter partes* review ("IPR") of U.S. Patent Number RE44,186 ("the RE'186 patent" or "the patent at issue").

5. I understand that the Patent Trial and Appeal Board has granted Mylan Pharmaceuticals Inc.'s ("Mylan" or "Petitioner") petition to institute this IPR regarding the RE'186 patent on obviousness grounds. I understand that the RE'186 patent, which is titled "Cyclopropyl-Fused Pyrrolidine-Based Inhibitors of Dipeptidyl Peptidase IV and Method," claims, among other things, the new chemical entity saxagliptin.¹

6. I understand further that the RE'186 patent is listed in the U.S. Food and Drug Administration's ("FDA") Approved Drug Products with Therapeutic Equivalence Evaluations ("the Orange Book") for the branded pharmaceutical drugs Onglyza[®] and KombiglyzeTM XR, which were developed by AstraZeneca in a collaboration agreement with Bristol-Myers Squibb Company ("BMS"), and are marketed in the U.S. by AstraZeneca.

7. I provide this declaration in regards to Patent Owner's arguments concerning objective indicia of non-obviousness. Specifically, I have been asked by counsel for AstraZeneca to evaluate the marketplace performance of Onglyza[®] (saxagliptin) and KombiglyzeTM XR (saxagliptin and metformin hydrochloride extended-release) and to provide an opinion regarding whether Onglyza[®] and KombiglyzeTM XR are a commercial success as a result of the patented features of the RE'186 patent.

C. Compensation

8. NERA is being compensated for the time I spend on this assignment at my customary hourly rate of \$675 and is separately reimbursed for reasonable

¹ Ex. 1001, 1, col. 3.

DOCKET A L A R M



Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.